Diabetes, Obesity and Endocrinology Disorders is a branch of science dealing with the endocrine glands and related disorders and a metabolic disorder deals with abnormal chemical reactions in the body alter the normal metabolic process. Endocrinology includes the study of hormones, the endocrine system, and their role in the physiology of the body. Endocrinology is a department of medicine which manages with the diagnosis and treatment of diseases related to hormones and also diagnostic evaluation of a wide variety of symptoms and variations and the long-term management of disorders of deficiency or excess of one or more hormones. Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger. If left untreated, diabetes can cause many complications. A metabolic disorder can occur when irregular chemical reactions in the body altering the normal metabolic pathway. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

People suffering from various endocrine disorders and endocrine cancers:

With the appalling increase in the prevalence of varied hormone-related medical conditions, like Endocrinology, Diabetes, Obesity, and Endocrinology, the world market for endocrinology medicine market has been witnessing a motivating upsurge in its overall size and valuation. Since the incidence rate of diabetes is exceptionally high across the globe, fueled by an unhealthy diet and also the reducing involvement of customers in physical activities, the world market is likely to maintain a high paced rise in the coming years. The endocrinology medication market in the Americas is anticipated to achieve USD 41 billion by 2020, growing at a CAGR of over 6%. The endocrinology medication market in EMEA can exceed USD 16 billion by 2020, growing at a CAGR of over 6%. The medicine medication market in APAC is anticipated to exceed USD 14 billion by 2020, growing at a CAGR of over 7% key suppliers being Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca, and AbbVie. Due to the high prevalence of diabetes, the demand for diabetes medicine is beyond other products. Researchers expect this trend to stay thus over consecutive few years, leading to the high rate of growth of the diabetes drug segment. The introduction of novel drug therapies and also the presence of strong product pipelines during this market for the treatment of both varieties of diabetes are possible to add considerably to the increase of this segment in the years to come.

• Endocrinology Summit 2020 Market Analysis for Endocrinology Summit